{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:36:55Z","timestamp":1771655815552,"version":"3.50.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Interleukin-6 (IL-6) is a multiple-effect cell factor implicated in the etiopathogenesis of several rheumatologic disorders. The blockade of the IL-6 pathway via IL6R inhibitors effectively treats these disorders. However, the clinical significance of the IL6R blockade for ankylosing spondylitis (AS) therapy remains controversial. With advances in genomics, increasing evidence has revealed the role of heritability in the etiology of disease, and Mendelian randomization (MR) analyses are being used more broadly to infer causation. Therefore, this MR study aims to evaluate the potential therapeutic utility of IL6R-targeted approaches in AS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The C-reactive protein (CRP) level was used as an exposure factor, and rheumatoid arthritis (RA) was used as a positive control. As-related genome-wide association study (GWAS) data were used as the primary outcome of drug-targeted MR analyses to test the relation between IL6R blockers and AS. Inverse variance weighting (IVW) is the primary analytical approach. Various sensitivity tests were performed to check the robustness and trustworthiness of the causality estimation, including consistency, heterogeneity, and pleiotropy analyses. In addition, repeated analysis was conducted using different GWAS data related to exposures and outcomes to examine the results for stability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to the IVW results, IL6R inhibitors significantly reduced the risk of AS in ukb-b-18194 (OR: 0.995, 95% CI 0.993\u20130.996, <jats:italic>P<\/jats:italic> = 5.12 \u00d7 10<jats:sup>\u221208<\/jats:sup>) and ukb-a-88 (OR: 0.994, 95% CI 0.993\u20130.996, <jats:italic>P<\/jats:italic> = 6.25 \u00d7 10<jats:sup>\u221215<\/jats:sup>). Moreover, repeated analyses were performed using different exposure-related GWAS data, yielding similar results, ukb-b-18194 (OR: 0.995, 95% CI 0.993\u20130.997, <jats:italic>P<\/jats:italic> = 1.25 \u00d7 10<jats:sup>\u221206<\/jats:sup>) and ukb-a-88 (OR: 0.995, 95% CI 0.994\u20130.997, <jats:italic>P<\/jats:italic> = 7.81 \u00d7 10<jats:sup>\u221209<\/jats:sup>). Heterogeneity analyses and pleiotropy analyses indicated no significant heterogeneity or pleiotropy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This MR analysis result further validates that the IL-6 pathway may contribute to the pathogenesis of AS and that the inhibition of IL6R reduces the risk of AS. These findings may guide future studies and provide more favorable drug treatment options for people at high risk of AS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1368346","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:43:15Z","timestamp":1716266595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic potential of single-nucleotide polymorphism-mediated IL6R inhibitors in ankylosing spondylitis treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Ding-Qiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Qiang","family":"Que","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai-Kun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di-Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Rui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD002822","DOI":"10.1002\/14651858.CD002822.pub3","article-title":"Physiotherapy interventions for ankylosing spondylitis","volume":"2008","author":"Dagfinrud","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.7326\/0003-4819-136-12-200206180-00011","article-title":"Update on spondyloarthropathies","volume":"136","author":"Khan","year":"2002","journal-title":"Ann Intern Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.23275","article-title":"Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatoryantiinflammatory drugs","volume":"58","author":"Song","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.55563\/clinexprheumatol\/qkiorp","article-title":"Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-\u03b1 inhibitors: a nationwide nested case-control analysis","volume":"41","author":"Kim","year":"2023","journal-title":"Clin Exp Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1302\/2058-5241.4.180047","article-title":"Bilateral total hip arthroplasty in ankylosing spondylitis: a systematic review","volume":"4","author":"Lin","year":"2019","journal-title":"EFORT Open Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e972","DOI":"10.1016\/j.wneu.2019.04.011","article-title":"Comparison of 2 surgeries in correction of severe kyphotic deformity caused by ankylosing spondylitis: vertebral column decancellation and pedicle subtraction osteotomy","volume":"127","author":"Wang","year":"2019","journal-title":"World Neurosurg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6540","DOI":"10.1038\/s41467-021-26750-6","article-title":"Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis","volume":"12","author":"Shao","year":"2021","journal-title":"Nat Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/157436209789057467","article-title":"Targeting JAK\/STAT signaling pathway in inflammatory diseases","volume":"4","author":"Malemud C","year":"2009","journal-title":"Curr Signal Transduct Ther."},{"key":"B10","first-page":"17362","article-title":"Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/labmed\/lmab029","article-title":"Serum IL-6 and TNF-\u03b1 levels are correlated with disease severity in patients with ankylosing spondylitis","volume":"53","author":"Du","year":"2022","journal-title":"Lab Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"155645","DOI":"10.1016\/j.cyto.2021.155645","article-title":"An update on the pathogenic role of IL-6 in rheumatic diseases","volume":"146","author":"Kaneko","year":"2021","journal-title":"Cytokine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2174\/187152812800958979","article-title":"Antagonizing IL-6 in ankylosing spondylitis: a short review","volume":"11","author":"Rajalingham","year":"2012","journal-title":"Inflamm Allergy Drug Targets."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e899","DOI":"10.1210\/clinem\/dgab757","article-title":"Causes and consequences of polycystic ovary syndrome: insights from Mendelian randomization","volume":"107","author":"Zhu","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1515\/cclm-2023-0086","article-title":"Why C-reactive protein is one of the most requested tests in clinical laboratories?","volume":"61","author":"Plebani","year":"2023","journal-title":"Clin Chem Lab Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1295412","DOI":"10.3389\/fendo.2023.1295412","article-title":"Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Endocrinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1160148","DOI":"10.3389\/fimmu.2023.1160148","article-title":"Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study","volume":"14","author":"Nolde","year":"2023","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"15228","DOI":"10.18632\/aging.205347","article-title":"Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study","volume":"15","author":"Chen","year":"2023","journal-title":"Aging."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","article-title":"MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data","volume":"46","author":"Yavorska","year":"2017","journal-title":"Int J Epidemiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur J Epidemiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fgene.2020.00254","article-title":"Serum uric acid level and multiple sclerosis: a Mendelian randomization study","volume":"11","author":"Niu","year":"2020","journal-title":"Front Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/bioinformatics\/btw373","article-title":"PhenoScanner: a database of human genotype-phenotype associations","volume":"32","author":"Staley","year":"2016","journal-title":"Bioinformatics."},{"key":"B27","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2015","journal-title":"Int Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/ard.2005.037465","article-title":"Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases","volume":"65","author":"Fran\u00e7ois","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratac\u00f3s","year":"1994","journal-title":"Br J Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/ard.53.6.425-b","article-title":"Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis","volume":"53","author":"Tutuncu","year":"1994","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/rheumatology\/36.3.400","article-title":"A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies","volume":"36","author":"Claudepierre","year":"1997","journal-title":"Br J Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s002960050066","article-title":"In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility","volume":"18","author":"Falkenbach","year":"1998","journal-title":"Rheumatol Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","article-title":"Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis","volume":"26","author":"Bal","year":"2007","journal-title":"Clin Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e002359","DOI":"10.1136\/rmdopen-2022-002359","article-title":"A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases","volume":"8","author":"Kastrati","year":"2022","journal-title":"RMD Open."},{"key":"B36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jbspin.2010.08.004","article-title":"Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists","volume":"77","author":"Brulhart","year":"2010","journal-title":"Joint Bone Spine."},{"key":"B37","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol."},{"key":"B38","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10165-011-0416-9","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis","volume":"21","author":"Shima","year":"2011","journal-title":"Mod Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.31138\/mjr.32.2.182","article-title":"Neutrophil extracellular traps and interleukin 17 in ankylosing spondylitis","volume":"32","author":"Papagoras","year":"2021","journal-title":"Mediterr J Rheumatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1084\/jem.167.3.1253","article-title":"B cell stimulating factor 2\/interleukin 6 is a costimulant for human thymocytes and T lymphocytes","volume":"167","author":"Lotz","year":"1988","journal-title":"J Exp Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0165-2478(02)00202-X","article-title":"Characterization of anti-mouse interleukin-6 receptor antibody","volume":"84","author":"Okazaki","year":"2002","journal-title":"Immunol Lett."},{"key":"B44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.biopha.2018.01.108","article-title":"Immune cells involved in the pathogenesis of ankylosing spondylitis","volume":"100","author":"Rezaiemanesh","year":"2018","journal-title":"Biomed Pharmacother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-2249.2004.02617.x","article-title":"Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus","volume":"138","author":"Yang","year":"2004","journal-title":"Clin Exp Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3892\/etm.2014.2046","article-title":"T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis","volume":"9","author":"Wang","year":"2015","journal-title":"Exp Ther Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature."},{"key":"B48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cyto.2015.01.003","article-title":"Update on the role of Interleukin 17 in rheumatologic autoimmune diseases","volume":"75","author":"Konya","year":"2015","journal-title":"Cytokine."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.4088\/JCP.15f10150","article-title":"Understanding relative risk, odds ratio, and related terms: as simple as it can get","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e001888","DOI":"10.1136\/rmdopen-2021-001888","article-title":"Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades","volume":"7","author":"Crossfield","year":"2021","journal-title":"RMD Open."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1368346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:43:19Z","timestamp":1716266599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1368346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":51,"alternative-id":["10.3389\/fmed.2024.1368346"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1368346","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"article-number":"1368346"}}